Effects of Topiramate on Smoking in Patients With Schizoaffective Disorder, Bipolar Type

Weinberger, Andrea H.; George, Tony P.; Perkins, Kenneth A.; Chengappa, K. N. Roy

doi:10.1097/jcp.0b013e31816740cf

Cited by 12 publications

(3 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For example, those who participate in clinical trials tend to be of higher SES than those in the community (Hanson and Chen, 2007). Lower SES is a risk factor for smoking, for persistent and is a barrier to access to smoking cessation treatment (Kiefe et al, 1998; Roddy et al, 2006; Schaap and Kunst, 2009; Weinberger et al, 2008). Additionally, clinical trials for smoking cessation generally exclude potential participants with current depression, as well as those with anxiety and substance use disorders, which are highly comorbid with both depression and smoking (Cox et al, 2008; Gierisch et al, 2012).…”

Section: Introductionmentioning

confidence: 99%

Major depressive disorder and smoking relapse among adults in the United States: A 10-year, prospective investigation

Zvolensky

Bakhshaie

Sheffer

et al. 2015

Psychiatry Research

View full text Add to dashboard Cite

This study investigated the relation between major depressive disorder (MDD) and smoking relapse in the U.S. over a 10-year period. Data were drawn from the Midlife Development in the United States (MIDUS) Survey Waves I & II. Logistic regression analyses were used to explore the associations between past-year MDD in 1994, past-year MDD in 2005 and persistent depression (1994 and 2005) and risk of smoking relapse in 2005 among former smokers, adjusting for demographics, anxiety disorders, and substance use problems and smoking characteristics. Among former smokers, MDD in 1994, compared to without MDD in 1994, was associated with significantly increased odds of smoking relapse by 2005. Current MDD in 2005 was associated with an even stronger risk of relapse in 2005 and persistent depression even more strongly predicted relapse by 2005. These associations remained significant and were not substantially attenuated by the covariates. In conclusion, MDD appears to confer long-term vulnerability to smoking relapse among adults in the general population. These results suggest interventions for smoking cessation should include screening and treatment for MDD if programs are to be optimally effective at achieving initial quit success as well as enduring abstinence.

show abstract

Section: Introductionmentioning

confidence: 99%

Major depressive disorder and smoking relapse among adults in the United States: A 10-year, prospective investigation

Zvolensky

Bakhshaie

Sheffer

et al. 2015

Psychiatry Research

View full text Add to dashboard Cite

show abstract

“…In particular, Khazaal et al (2006) found a significant rate of smoking cessation in a small sample of patients treated with topiramate, while Anthenelli et al (2006) did not find statistical differences between topiramate and placebo, although a trend of reduction in smoked cigarettes was found in male smokers treated with topiramate. A secondary analysis of an 8-week placebo-controlled, randomized clinical trial examining the safety and efficacy of topiramate for patients with schizoaffective disorder, bipolar type, showed a lack of effect on smoking in this subtype of patients (Weinberger et al, 2008). Finally, Baltieri et al (2009) found a reduction in cigarette smoking among alcoholic patients treated with topiramate.…”

Section: Topiramatementioning

confidence: 99%

Novel Therapeutic Strategies for Alcohol and Drug Addiction: Focus on GABA, Ion Channels and Transcranial Magnetic Stimulation

Addolorato

Leggio

Hopf

et al. 2011

Neuropsychopharmacol

View full text Add to dashboard Cite

Drug addiction represents a major social problem where addicts and alcoholics continue to seek and take drugs despite adverse social, personal, emotional, and legal consequences. A number of pharmacological compounds have been tested in human addicts with the goal of reducing the level or frequency of intake, but these pharmacotherapies have often been of only moderate efficacy or act in a sub-population of humans. Thus, there is a tremendous need for new therapeutic interventions to treat addiction. Here, we review recent interesting studies focusing on gamma-aminobutyric acid receptors, voltage-gated ion channels, and transcranial magnetic stimulation. Some of these treatments show considerable promise to reduce addictive behaviors, or the early clinical studies or pre-clinical rationale suggest that a promising avenue could be developed. Thus, it is likely that within a decade or so, we could have important new and effective treatments to achieve the goal of reducing the burden of human addiction and alcoholism.

show abstract

“…We recently published a secondary analysis of expired breath carbon monoxide (CO) levels (a measure of smoking exposure) in patients with schizoaffective disorder, bipolar subtype, participating in a clinical trial of topiramate for treating psychiatric symptoms (1). Our analysis found that CO levels remained generally unchanged for participants on topiramate and placebo during the course of the trial.…”

mentioning

confidence: 99%